Association of serum metabolome profile with the risk of breast cancer in participants of the HUNT2 study.
breast cancer
cancer risk
metabolic profiling
population study
serum metabolome
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
12
2022
accepted:
06
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
The serum metabolome is a potential source of molecular biomarkers associated with the risk of breast cancer. Here we aimed to analyze metabolites present in pre-diagnostic serum samples collected from healthy women participating in the Norwegian Trøndelag Health Study (HUNT2 study) for whom long-term information about developing breast cancer was available. Women participating in the HUNT2 study who developed breast cancer within a 15-year follow-up period (BC cases) and age-matched women who stayed breast cancer-free were selected ( Age was a major confounding factor responsible for a large heterogeneity in the dataset, hence age-defined subgroups were analyzed separately. The largest number of metabolites whose serum levels differentiated BC cases and controls (82 compounds) were observed in the subgroup of younger women (<45 years old). Noteworthy, increased levels of glycerides, phosphatidylcholines, and sphingolipids were associated with reduced risk of cancer in younger and middle-aged women (≤64 years old). On the other hand, increased levels of serum lipids were associated with an enhanced risk of breast cancer in older women (>64 years old). Moreover, several metabolites could be detected whose serum levels were different between BC cases diagnosed earlier (<5 years) and later (>10 years) after sample collecting, yet these compounds were also correlated with the age of participants. Current results were coherent with the results of the NMR-based metabolomics study performed in the cohort of HUNT2 participants, where increased serum levels of VLDL subfractions were associated with reduced risk of breast cancer in premenopausal women. Changes in metabolite levels detected in pre-diagnostic serum samples, which reflected an impaired lipid and amino acid metabolism, were associated with long-term risk of breast cancer in an age-dependent manner.
Sections du résumé
Background
UNASSIGNED
The serum metabolome is a potential source of molecular biomarkers associated with the risk of breast cancer. Here we aimed to analyze metabolites present in pre-diagnostic serum samples collected from healthy women participating in the Norwegian Trøndelag Health Study (HUNT2 study) for whom long-term information about developing breast cancer was available.
Methods
UNASSIGNED
Women participating in the HUNT2 study who developed breast cancer within a 15-year follow-up period (BC cases) and age-matched women who stayed breast cancer-free were selected (
Results
UNASSIGNED
Age was a major confounding factor responsible for a large heterogeneity in the dataset, hence age-defined subgroups were analyzed separately. The largest number of metabolites whose serum levels differentiated BC cases and controls (82 compounds) were observed in the subgroup of younger women (<45 years old). Noteworthy, increased levels of glycerides, phosphatidylcholines, and sphingolipids were associated with reduced risk of cancer in younger and middle-aged women (≤64 years old). On the other hand, increased levels of serum lipids were associated with an enhanced risk of breast cancer in older women (>64 years old). Moreover, several metabolites could be detected whose serum levels were different between BC cases diagnosed earlier (<5 years) and later (>10 years) after sample collecting, yet these compounds were also correlated with the age of participants. Current results were coherent with the results of the NMR-based metabolomics study performed in the cohort of HUNT2 participants, where increased serum levels of VLDL subfractions were associated with reduced risk of breast cancer in premenopausal women.
Conclusions
UNASSIGNED
Changes in metabolite levels detected in pre-diagnostic serum samples, which reflected an impaired lipid and amino acid metabolism, were associated with long-term risk of breast cancer in an age-dependent manner.
Identifiants
pubmed: 37007110
doi: 10.3389/fonc.2023.1116806
pmc: PMC10061137
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1116806Informations de copyright
Copyright © 2023 Mrowiec, Kurczyk, Jelonek, Debik, Giskeødegård, Bathen and Widłak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Epidemiol. 2013 Aug;42(4):968-77
pubmed: 22879362
Metabolomics. 2018 Jul 6;14(7):97
pubmed: 30830410
Int J Mol Sci. 2020 Jun 24;21(12):
pubmed: 32599910
Scand J Clin Lab Invest. 2019 Feb - Apr;79(1-2):17-24
pubmed: 30880483
Int J Biol Sci. 2014 Aug 30;10(9):966-72
pubmed: 25210494
Maturitas. 1990 Sep;12(3):259-85
pubmed: 2145495
Environ Health Perspect. 2011 Mar;119(3):351-6
pubmed: 21097385
Nat Commun. 2014 Aug 21;5:4708
pubmed: 25144627
Int J Epidemiol. 2018 Apr 1;47(2):484-494
pubmed: 29365091
Metabolomics. 2021 Jan 29;17(2):20
pubmed: 33515103
Crit Rev Oncol Hematol. 2021 Jan;157:103174
pubmed: 33249359
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562706
Cancers (Basel). 2021 Jan 05;13(1):
pubmed: 33466323
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
BMJ. 2020 Oct 28;371:m3873
pubmed: 33115755
Metabolomics. 2018 Jun 8;14(6):85
pubmed: 30830383
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):11-6
pubmed: 12524219
Cancers (Basel). 2021 May 31;13(11):
pubmed: 34072693
Am J Obstet Gynecol. 1999 Aug;181(2):430-4
pubmed: 10454696
Onco Targets Ther. 2019 Aug 21;12:6797-6811
pubmed: 31686838
Fertil Steril. 2001 May;75(5):898-915
pubmed: 11334901
Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):839-850
pubmed: 35064065
Nutrients. 2021 Dec 20;13(12):
pubmed: 34960109
Cancer Treat Rev. 2018 Jun;67:88-96
pubmed: 29775779
Metabolites. 2021 Feb 10;11(2):
pubmed: 33578791
Am J Prev Cardiol. 2022 Mar 13;10:100333
pubmed: 35345879
J Clin Invest. 2013 Sep;123(9):3678-84
pubmed: 23999442
Br J Cancer. 2021 May;124(10):1734-1743
pubmed: 33723391
Br J Cancer. 2020 Jan;122(1):4-22
pubmed: 31819192
BMC Med. 2016 Jan 28;14:13
pubmed: 26817443
Br J Cancer. 2022 Nov;127(8):1515-1524
pubmed: 35927310
NPJ Breast Cancer. 2021 May 18;7(1):54
pubmed: 34006878
Oncotarget. 2017 Mar 21;8(12):19522-19533
pubmed: 28076849
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 15;1105:26-37
pubmed: 30562627
J Natl Cancer Inst. 2018 Jun 1;110(6):588-597
pubmed: 29325144
BMC Med. 2019 Sep 24;17(1):178
pubmed: 31547832
Epidemiol Rev. 1993;15(1):36-47
pubmed: 8405211